MA41937B1 - Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 - Google Patents
Conjugués de médicaments comprenant des anticorps contre la claudine 18.2Info
- Publication number
- MA41937B1 MA41937B1 MA41937A MA41937A MA41937B1 MA 41937 B1 MA41937 B1 MA 41937B1 MA 41937 A MA41937 A MA 41937A MA 41937 A MA41937 A MA 41937A MA 41937 B1 MA41937 B1 MA 41937B1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- claudine
- antibodies
- drug conjugates
- conjugates including
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 201000010175 gallbladder cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne des conjugués médicament-anticorps anti-cldn18.2 qui sont efficaces pour traiter et/ou prévenir des cancers associés à des cellules exprimant cldn18.2, dont le cancer de l'estomac, le cancer de l'œsophage, le cancer du pancréas, le cancer du poumon, le cancer de l'ovaire, le cancer du côlon, le cancer du foie, le cancer de la tête et du cou et le cancer de la vésicule biliaire et leurs métastases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/058206 WO2016165762A1 (fr) | 2015-04-15 | 2015-04-15 | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 |
PCT/EP2016/058056 WO2016166122A1 (fr) | 2015-04-15 | 2016-04-13 | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA41937A MA41937A (fr) | 2018-02-28 |
MA41937B1 true MA41937B1 (fr) | 2023-12-29 |
Family
ID=52875694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41937A MA41937B1 (fr) | 2015-04-15 | 2016-04-13 | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 |
Country Status (28)
Country | Link |
---|---|
US (2) | US11541127B2 (fr) |
EP (2) | EP4331578A3 (fr) |
JP (4) | JP6800883B2 (fr) |
KR (4) | KR102336566B1 (fr) |
CN (1) | CN107667118A (fr) |
AU (1) | AU2016249782B2 (fr) |
BR (1) | BR112017018521A2 (fr) |
CA (1) | CA2982401C (fr) |
DK (1) | DK3283521T3 (fr) |
ES (1) | ES2964813T3 (fr) |
FI (1) | FI3283521T3 (fr) |
HK (1) | HK1247210A1 (fr) |
HR (1) | HRP20231609T1 (fr) |
HU (1) | HUE064753T2 (fr) |
IL (1) | IL254085A0 (fr) |
LT (1) | LT3283521T (fr) |
MA (1) | MA41937B1 (fr) |
MD (1) | MD3283521T2 (fr) |
MX (2) | MX2017013075A (fr) |
PL (1) | PL3283521T3 (fr) |
PT (1) | PT3283521T (fr) |
RS (1) | RS64951B1 (fr) |
RU (2) | RU2017139490A (fr) |
SG (2) | SG11201708271TA (fr) |
SI (1) | SI3283521T1 (fr) |
UA (1) | UA127469C2 (fr) |
WO (2) | WO2016165762A1 (fr) |
ZA (1) | ZA201705923B (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2678127C2 (ru) | 2012-11-13 | 2019-01-23 | Бионтех Аг | Агенты для лечения экспрессирующих клаудин раковых заболеваний |
WO2016165762A1 (fr) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 |
IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
WO2019173420A1 (fr) | 2018-03-08 | 2019-09-12 | Phanes Therapeutics, Inc. | Anticorps anti-claudine 18.2 et leurs utilisations |
JP2021515583A (ja) | 2018-03-14 | 2021-06-24 | ベイジン シュアンイー ファーマサイエンシーズ カンパニー, リミテッド | 抗クローディン18.2抗体 |
CN110606891B (zh) * | 2018-06-17 | 2022-12-06 | 上海健信生物医药科技有限公司 | 一种针对人cldn18.2的抗体分子,抗原结合片段及其医药用途 |
JP7468903B2 (ja) * | 2018-06-17 | 2024-04-16 | エルアンドエル バイオファーマ カンパニー リミテッド | Cldn18.2を標的とする抗体、二重特異性抗体、adc及びcarならびにその使用 |
WO2020009165A1 (fr) * | 2018-07-03 | 2020-01-09 | 味の素株式会社 | Anticorps modifié et procédé pour sa production |
WO2020038404A1 (fr) * | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | Anticorps monoclonal anti-claudine 18,2 humaine et son utilisation |
CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
CN110862454B (zh) * | 2018-08-27 | 2022-12-30 | 南京圣和药业股份有限公司 | 一种抗Claudin18_2抗体及其应用 |
KR20210093879A (ko) * | 2018-10-22 | 2021-07-28 | 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. | 항-cldn18.2 항체 및 이의 용도 |
CN113423735B (zh) * | 2018-12-07 | 2024-02-13 | 再鼎医药(上海)有限公司 | 抗-紧密连接蛋白抗体及其用途 |
CN113166246A (zh) * | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
JP2022515487A (ja) * | 2018-12-28 | 2022-02-18 | ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド | クローディン18.2結合部分およびその利用 |
CN116333141A (zh) * | 2019-01-15 | 2023-06-27 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
CN113645996B (zh) * | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
KR20210144792A (ko) * | 2019-03-29 | 2021-11-30 | 페인스 테라퓨틱스 인코포레이티드 | 인간화된 항-클라우딘 18.2 키메라 항원 수용체 및 그의 용도 |
TW202102546A (zh) | 2019-04-01 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 密蛋白抗體及其應用 |
KR20220024010A (ko) * | 2019-05-16 | 2022-03-03 | 치루 파머수티컬 컴퍼니 리미티드 | 클라우딘 18a2에 대한 항체 및 그의 용도 |
CN117264059A (zh) * | 2019-05-16 | 2023-12-22 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
CN113891731A (zh) * | 2019-05-22 | 2022-01-04 | 小利兰·斯坦福大学理事会 | 药物缀合物及其使用方法 |
KR20220006085A (ko) * | 2019-05-30 | 2022-01-14 | 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 | 클라우딘(Claudin) 18.2를 표적화하는 항체 또는 키메라 항원 수용체 |
MX2022000652A (es) | 2019-07-17 | 2022-06-02 | Univ California | Anticuerpos contra claudina 18 y metodos de tratamiento del cancer. |
WO2021032157A1 (fr) * | 2019-08-20 | 2021-02-25 | Mabspace Biosciences (Suzhou) Co., Limited | Nouveaux anticorps anti-cldn18.2 |
WO2021047599A1 (fr) * | 2019-09-13 | 2021-03-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anticorps humanisés anti-claudine 18.2 (cldn18.2) |
CN112707965A (zh) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | 靶向cldn18.2的抗体及其制备方法和应用 |
CN114269389B (zh) * | 2019-11-05 | 2022-12-27 | 礼新医药科技(上海)有限公司 | 靶向紧密连接蛋白18.2的抗体药物偶联物 |
AU2020398045A1 (en) | 2019-12-06 | 2022-06-09 | Sotio Biotech A.S. | Humanized CLDN18.2 antibodies |
WO2021115426A1 (fr) | 2019-12-12 | 2021-06-17 | 江苏恒瑞医药股份有限公司 | Conjugué anticorps anti-claudine-médicament et son utilisation pharmaceutique |
JP2023507664A (ja) | 2019-12-23 | 2023-02-24 | ソティオ バイオテック エイ.エス. | 腫瘍特異的クローディン18.2抗体 |
US20230192841A1 (en) * | 2019-12-27 | 2023-06-22 | Nanjing Legend Biotech Co., Ltd. | Claudin18.2 binding moieties and uses thereof |
US20230331836A1 (en) * | 2020-05-25 | 2023-10-19 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-cldn18.2 antibodies and diagnostic uses thereof |
CN111704669B (zh) * | 2020-07-13 | 2022-05-13 | 北京凯因科技股份有限公司 | 一种用于治疗晚期胃癌的抗cldn18全人源化抗体 |
CN113929780A (zh) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
WO2022011531A1 (fr) * | 2020-07-14 | 2022-01-20 | 浙江道尔生物科技有限公司 | Anticorps à domaine unique anti-cld18a2 |
US20230312725A1 (en) | 2020-08-28 | 2023-10-05 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Signal peptide for reducing end heterogeneity of heterologous polypeptide |
CA3193104A1 (fr) | 2020-09-30 | 2022-04-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Composition pharmaceutique comprenant un conjugue anticorps-medicament, et utilisation de la composition pharmaceutique |
CN114366818A (zh) * | 2020-10-15 | 2022-04-19 | 上海美雅珂生物技术有限责任公司 | 抗体药物偶联物及其应用 |
WO2022100590A1 (fr) * | 2020-11-10 | 2022-05-19 | 齐鲁制药有限公司 | Anticorps humanisé enrichi en adcc pour claudin 18a2 et application associée |
CN112480248B (zh) * | 2020-11-24 | 2023-05-05 | 三优生物医药(上海)有限公司 | 与cld18a2特异性结合的分子 |
CN116669730A (zh) | 2020-11-30 | 2023-08-29 | 石药集团巨石生物制药有限公司 | 抗cldn18.2抗体、药物偶联物及其制备方法和用途 |
WO2022122709A1 (fr) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Conjugués anticorps-médicament à base d'anticorps cldn18.2 humanisés |
JP2024500242A (ja) | 2020-12-23 | 2024-01-05 | ソティオ バイオテック エイ.エス. | 腫瘍特異的クローディン18.2抗体と薬物との複合体 |
CN114904015A (zh) * | 2021-02-09 | 2022-08-16 | 江苏迈威康新药研发有限公司 | 包含抗cldn18.2的抗体或其抗原结合片段的抗体药物偶联物及其用途 |
AU2022325498A1 (en) | 2021-08-13 | 2024-02-01 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
WO2023025303A1 (fr) * | 2021-08-26 | 2023-03-02 | 上海君实生物医药科技股份有限公司 | Conjugué anticorps-médicament anti-cldn-18.2 et son utilisation |
CN115991784A (zh) | 2021-10-19 | 2023-04-21 | 宝船生物医药科技(上海)有限公司 | 抗cd47-cldn18.2双特异性抗体及其用途 |
CN117143237A (zh) * | 2022-06-01 | 2023-12-01 | 百奥泰生物制药股份有限公司 | 抗cldn18.2抗体及其抗体药物偶联物和用途 |
CN117229398A (zh) * | 2022-06-15 | 2023-12-15 | 中山康方生物医药有限公司 | 抗cldn18.2抗体、其药物组合物及用途 |
CN115969997B (zh) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | 一种靶向cldn18.2的抗体药物偶联物及其应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (fr) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotique C-15003 PHO et sa préparation |
WO1982001188A1 (fr) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | Composes 4,5-deoxymaytansinoide et leur procede de preparation |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2004035607A2 (fr) | 2002-10-17 | 2004-04-29 | Genmab A/S | Anticorps monoclonaux humains anti-cd20 |
DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) * | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1997832A1 (fr) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer |
US20100316639A1 (en) * | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
BR112013014316A2 (pt) * | 2010-12-09 | 2016-09-27 | Genentech Inc | tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1 |
WO2013085925A1 (fr) * | 2011-12-05 | 2013-06-13 | Igenica, Inc. | Conjugués anticorps-médicament et composés, compositions et méthodes connexes |
WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
WO2013174404A1 (fr) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
WO2014146672A1 (fr) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer |
WO2015014376A1 (fr) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses |
WO2016165762A1 (fr) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 |
WO2016165765A1 (fr) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer |
-
2015
- 2015-04-15 WO PCT/EP2015/058206 patent/WO2016165762A1/fr active Application Filing
-
2016
- 2016-04-13 PL PL16715583.7T patent/PL3283521T3/pl unknown
- 2016-04-13 ES ES16715583T patent/ES2964813T3/es active Active
- 2016-04-13 EP EP23209136.3A patent/EP4331578A3/fr active Pending
- 2016-04-13 SG SG11201708271TA patent/SG11201708271TA/en unknown
- 2016-04-13 LT LTEPPCT/EP2016/058056T patent/LT3283521T/lt unknown
- 2016-04-13 PT PT167155837T patent/PT3283521T/pt unknown
- 2016-04-13 SG SG10202105142VA patent/SG10202105142VA/en unknown
- 2016-04-13 BR BR112017018521A patent/BR112017018521A2/pt active Search and Examination
- 2016-04-13 KR KR1020177029588A patent/KR102336566B1/ko active IP Right Grant
- 2016-04-13 AU AU2016249782A patent/AU2016249782B2/en active Active
- 2016-04-13 US US15/565,848 patent/US11541127B2/en active Active
- 2016-04-13 WO PCT/EP2016/058056 patent/WO2016166122A1/fr active Application Filing
- 2016-04-13 KR KR1020227016552A patent/KR102626316B1/ko active IP Right Grant
- 2016-04-13 KR KR1020217039609A patent/KR102401299B1/ko active IP Right Grant
- 2016-04-13 DK DK16715583.7T patent/DK3283521T3/da active
- 2016-04-13 FI FIEP16715583.7T patent/FI3283521T3/fi active
- 2016-04-13 KR KR1020247001267A patent/KR20240011250A/ko active Application Filing
- 2016-04-13 HU HUE16715583A patent/HUE064753T2/hu unknown
- 2016-04-13 RU RU2017139490A patent/RU2017139490A/ru unknown
- 2016-04-13 EP EP16715583.7A patent/EP3283521B1/fr active Active
- 2016-04-13 MD MDE20180164T patent/MD3283521T2/ro unknown
- 2016-04-13 CA CA2982401A patent/CA2982401C/fr active Active
- 2016-04-13 UA UAA201711145A patent/UA127469C2/uk unknown
- 2016-04-13 MX MX2017013075A patent/MX2017013075A/es unknown
- 2016-04-13 RU RU2021131990A patent/RU2021131990A/ru unknown
- 2016-04-13 RS RS20231193A patent/RS64951B1/sr unknown
- 2016-04-13 JP JP2017552461A patent/JP6800883B2/ja active Active
- 2016-04-13 CN CN201680021997.6A patent/CN107667118A/zh active Pending
- 2016-04-13 MA MA41937A patent/MA41937B1/fr unknown
- 2016-04-13 HR HRP20231609TT patent/HRP20231609T1/hr unknown
- 2016-04-13 SI SI201631779T patent/SI3283521T1/sl unknown
-
2017
- 2017-08-21 IL IL254085A patent/IL254085A0/en unknown
- 2017-08-31 ZA ZA2017/05923A patent/ZA201705923B/en unknown
- 2017-10-11 MX MX2023013476A patent/MX2023013476A/es unknown
-
2018
- 2018-05-17 HK HK18106396.7A patent/HK1247210A1/zh unknown
-
2020
- 2020-11-25 JP JP2020195120A patent/JP7024152B2/ja active Active
-
2021
- 2021-12-24 JP JP2021210851A patent/JP2022031979A/ja active Pending
-
2022
- 2022-12-06 US US18/062,494 patent/US20230270878A1/en active Pending
-
2024
- 2024-01-31 JP JP2024012973A patent/JP2024036444A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41937B1 (fr) | Conjugués de médicaments comprenant des anticorps contre la claudine 18.2 | |
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
HK1259487A1 (zh) | 特定的共軛連接子,特定的免疫共軛物,製造和使用這些共軛物的方法 | |
IL268888A (en) | Multispecific binding proteins targeting CAIX, ANOI, mesothelin, TROP2, CEA, or CLAUDIN-18.2 | |
SA518400222B1 (ar) | أجسام مضادة لـ وتركيبات tim-3 | |
CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
MX2020011795A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
PH12018500285A1 (en) | Bridge linkers for conjugation of a cell-binding molecule | |
MX2020011780A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MA44890A (fr) | Compositions comprenant des souches bactériennes | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2016009862A (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
EA201591559A1 (ru) | Терапевтические пептиды | |
WO2017136659A3 (fr) | Anticorps humanisés anti-cd3, conjugués et leurs utilisations | |
MX2021015533A (es) | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. | |
CY1123593T1 (el) | Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου | |
PH12020550964A1 (en) | Heavy chain antibodies binding to cd22 | |
PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
FR3096259B1 (fr) | conjugués anticorps-médicament et leur utilisation en thérapie | |
SA519401424B1 (ar) | Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها | |
MX2020002802A (es) | Anticuerpos de cadena pesada que se unen a ectoenzimas. | |
MX2018011219A (es) | Trail diseñado por ingenieria para terapia de cancer. | |
MA45476A (fr) | Compositions comprenant des souches bactériennes | |
MA45200A (fr) | Compositions comprenant des souches bactériennes |